Publications

Detailed Information

Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy

Cited 4 time in Web of Science Cited 4 time in Scopus
Authors

Kim, E. J.; Yu, K. -S.; Na, S. H.; Nam, E. Y.; Oh, H. S.; Kim, M.; Yoon, S. H.; Lee, J-O; Koh, Y.; Song, K. -H.; Choe, P. G.; Cho, J. -Y.; Song, S. H.; Kim, E. S.; Kim, H. B.; Bang, S. -M.; Kim, N. J.; Oh, M.-D.; Kim, I.; Park, W. B.

Issue Date
2017-12
Publisher
Elsevier Masson
Citation
Journal de Mycologie Medicale, Vol.27 No.4, pp.539-542
Abstract
Absorption of posaconazole oral suspension is influenced by several factors including diet, medications, and mucosal integrity. However, there are few prospective data about which is the most important modifiable factor in routine clinical practice. We prospectively analyzed clinical risk factors associated with low posaconazole trough concentrations in 114 patients receiving anticancer chemotherapy due to acute myeloid leukemia or myelodysplastic syndrome who received posaconazole oral suspension. In multivariate analyses, risk factors for drug level < 500 ng/mL included low calorie intake, mucositis >= grade 2, H-2 blocker famotidine and proton-pump inhibitor. The only significant risk factor for drug level < 700 ng/mL was famotidine use (adjusted relative risk, 3.18; 95% confidence interval, 1.07-9.11; P= 0.038). In conclusion, medication of H-2 blocker famotidine should be cautious in patients with hematologic malignancy receiving posaconazole suspension. (C) 2017 Elsevier Masson SAS. All rights reserved.
ISSN
1156-5233
URI
https://hdl.handle.net/10371/199671
DOI
https://doi.org/10.1016/j.mycmed.2017.08.001
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Immunology, Infectious Diseases, Vaccination, 감염병, 바이러스질환, 예방접종

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share